National Engineering Research Center for Biomaterials, Sichuan University, Chengdu, Sichuan 610064, People's Republic of China.
J Mater Chem B. 2020 Jun 24;8(24):5267-5279. doi: 10.1039/d0tb00539h.
Nowadays, cancer therapy faces severe challenges regarding boosting therapeutic efficiency and reducing the side effects of drugs. To overcome these challenges, herein multifunctional polymeric prodrug micelles combining chemotherapy and photodynamic therapy are put forward; the multifunctional polymeric prodrug micelles are prepared through self-assembly of amphipathic copolymer and photosensitizer Chlorin e6 (Ce6). These therapeutic prodrug micelles have better intracellular uptake and deeper tumor infiltration through charge reversal and smaller size changes, respectively. The polymeric prodrug micelles have fast disassembly and release Ce6 in the case of cathepsin B existence in the lysosome. Under light irradiation at 660 nm, Ce6 can efficiently generate singlet oxygen and accelerate the release of gemcitabine (GEM) by destroying the bis-(alkylthio) alkene functional group, which is the singlet-oxygen responsive linker, to achieve the combination of chemotherapy and photodynamic therapy (PDT). Under light irradiation at 660 nm, the singlet oxygen can also efficiently destroy mitochondrial functions to activate mitochondria apoptosis pathways, including increased reactive oxygen species (ROS) levels and swollen mitochondria. Further, employing 4T1-bearing BALB/c mice as a model, the anticancer effect of the therapeutic prodrug micelles is systematically investigated in vivo. The therapeutic prodrug micelles show an efficient tumor growth inhibition in vivo after light irradiation. Meanwhile, therapeutic prodrug micelles can significantly reduce adverse effects compared with the free drug, exhibiting better biocompatibility. Therefore, this prodrug micelle with a triple sensitivity response and synergistic chemo-photodynamic therapy functions is expected to offer promising applications in efficient antitumor therapy.
如今,癌症治疗在提高治疗效率和降低药物副作用方面面临着严峻的挑战。为了克服这些挑战,本文提出了一种将化疗和光动力疗法相结合的多功能聚合物前药胶束;该多功能聚合物前药胶束通过两亲性共聚物和光敏剂氯[e6](Ce6)自组装而成。这些治疗前药胶束通过电荷反转和较小的尺寸变化分别具有更好的细胞内摄取和更深的肿瘤渗透能力。聚合物前药胶束在溶酶体中存在组织蛋白酶 B 的情况下快速解组装并释放 Ce6。在 660nm 光照射下,Ce6 可以有效地产生单线态氧,并通过破坏双(烷硫基)烯烃功能基团(单线态氧响应性连接子)来加速吉西他滨(GEM)的释放,从而实现化疗和光动力疗法(PDT)的结合。在 660nm 光照射下,单线态氧还可以有效地破坏线粒体功能,激活线粒体凋亡途径,包括增加活性氧(ROS)水平和肿胀的线粒体。此外,本文采用 4T1 荷瘤 BALB/c 小鼠作为模型,系统地研究了治疗前药胶束在体内的抗癌效果。在光照射后,治疗前药胶束在体内显示出高效的肿瘤生长抑制作用。同时,与游离药物相比,治疗前药胶束可以显著降低不良反应,表现出更好的生物相容性。因此,这种具有三重敏感响应和协同化-光动力治疗功能的前药胶束有望在高效抗肿瘤治疗中得到应用。